Rheumatoid Arthritis

Rheumatoid Arthritis | Pharmacor | G7 | 2015

Last Updated 14 December 2015
The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving…

Rheumatoid Arthritis | Chart Trends | US | 2015

ChartTrends: Rheumatoid Arthritis 2015 (US) provides insight into the management and treatment of RA patients by rheumatologists based on actual patient-level data. 224 U.S. rheumatologists…

Rheumatoid Arthritis | Decision Base | US | 2015

Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs?

Nine biologics are approved to treat rheumatoid arthritis (RA),…

Rheumatoid Arthritis | Pharmacor | G7 | 2015

Last Updated 15 December 2014
Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…